Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India

doi:10.1128/JCM.05966-11

Case Reports

. 2012 Apr;50(4):1478-9.

doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India

Krishna Pandey¹, V N R Das, Dharmendra Singh, Sushmita Das, C S Lal, N Verma, S Bimal, R K Topno, N A Siddiqui, R B Verma, P K Sinha, Pradeep Das

Affiliations

PMID: 22278840
PMCID: PMC3318524
DOI: 10.1128/JCM.05966-11

Case Reports

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India

Krishna Pandey et al. J Clin Microbiol. 2012 Apr.

. 2012 Apr;50(4):1478-9.

doi: 10.1128/JCM.05966-11. Epub 2012 Jan 25.

Authors

Krishna Pandey¹, V N R Das, Dharmendra Singh, Sushmita Das, C S Lal, N Verma, S Bimal, R K Topno, N A Siddiqui, R B Verma, P K Sinha, Pradeep Das

Affiliation

¹ Rajendra Memorial Research Institute of Medical Sciences (Indian Council of Medical Research), Agamkuan, Patna, Bihar, India. drkrishnapandey@yahoo.com

PMID: 22278840
PMCID: PMC3318524
DOI: 10.1128/JCM.05966-11

Abstract

Post kala-azar dermal leishmaniasis (PKDL) is a skin manifestation that usually develops after treatment of visceral leishmaniasis (VL), a major public health problem in India. The diagnosis and management of PKDL is complex. This is the first case report from India in which PKDL occurred after paromomycin treatment for VL in an Indian patient.

PubMed Disclaimer

Cited by

Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A, Singh VK, Tiwari R, Madhukar P, Rajneesh, Kumar S, Gautam V, Engwerda C, Sundar S, Kumar R. Kumar A, et al. Front Immunol. 2023 Aug 11;14:1236952. doi: 10.3389/fimmu.2023.1236952. eCollection 2023. Front Immunol. 2023. PMID: 37638047 Free PMC article. Review.
Leishmaniasis: where are we and where are we heading?
Sasidharan S, Saudagar P. Sasidharan S, et al. Parasitol Res. 2021 May;120(5):1541-1554. doi: 10.1007/s00436-021-07139-2. Epub 2021 Apr 7. Parasitol Res. 2021. PMID: 33825036 Review.
Mixed Cutaneous Infection Caused by Leishmania and Dermatophytes: A Rare Coincidence or Immunological Fact.
Singh AK, Kumar A, Pandey J, Gaur V, Tripathi P, Adhikari IP. Singh AK, et al. Case Rep Dermatol Med. 2021 Mar 8;2021:5526435. doi: 10.1155/2021/5526435. eCollection 2021. Case Rep Dermatol Med. 2021. PMID: 33763264 Free PMC article.
A randomized, open-label study to evaluate the efficacy and safety of liposomal amphotericin B (AmBisome) versus miltefosine in patients with post-kala-azar dermal leishmaniasis.
Pandey K, Pal B, Siddiqui NA, Lal CS, Ali V, Bimal S, Kumar A, Verma N, Das VNR, Singh SK, Topno RK, Das P. Pandey K, et al. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):34-41. doi: 10.25259/IJDVL_410_19. Indian J Dermatol Venereol Leprol. 2021. PMID: 33580944 Clinical Trial.
Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India.
Goyal V, Das VNR, Singh SN, Singh RS, Pandey K, Verma N, Hightower A, Rijal S, Das P, Alvar J, Bern C, Alves F. Goyal V, et al. PLoS Negl Trop Dis. 2020 Jul 20;14(7):e0008429. doi: 10.1371/journal.pntd.0008429. eCollection 2020 Jul. PLoS Negl Trop Dis. 2020. PMID: 32687498 Free PMC article. Clinical Trial.

See all "Cited by" articles

References

1. Das VNR, et al. 2009. Development of post kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg. 80:336–338 - PubMed
1. Dutta M, Ghosh TK. 1983. Review of current status of leishmaniasis epidemiology, p 97–102 Proceedings of the Indo-UK Workshop on Leishmaniasis Indian Council of Medical Research, New Delhi, India
1. Salotra P, et al. 2001. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J. Clin. Microbiol. 39:849–854 - PMC - PubMed
1. Singh S, Sundar S. 1995. Treatment of post-kala-azar dermal leishmaniasis. Int. J. Dermatol. 34:668–669 - PubMed
1. Singh SP, et al. 2011. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS 5:e960 - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Das VNR, et al. 2009. Development of post kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg. 80:336–338 - PubMed

[2] Das VNR, et al. 2009. Development of post kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am. J. Trop. Med. Hyg. 80:336–338 - PubMed

[3] Dutta M, Ghosh TK. 1983. Review of current status of leishmaniasis epidemiology, p 97–102 Proceedings of the Indo-UK Workshop on Leishmaniasis Indian Council of Medical Research, New Delhi, India

[4] Dutta M, Ghosh TK. 1983. Review of current status of leishmaniasis epidemiology, p 97–102 Proceedings of the Indo-UK Workshop on Leishmaniasis Indian Council of Medical Research, New Delhi, India

[5] Salotra P, et al. 2001. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J. Clin. Microbiol. 39:849–854 - PMC - PubMed

[6] Salotra P, et al. 2001. Development of a species-specific PCR assay for detection of Leishmania donovani in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. J. Clin. Microbiol. 39:849–854 - PMC - PubMed

[7] Singh S, Sundar S. 1995. Treatment of post-kala-azar dermal leishmaniasis. Int. J. Dermatol. 34:668–669 - PubMed

[8] Singh S, Sundar S. 1995. Treatment of post-kala-azar dermal leishmaniasis. Int. J. Dermatol. 34:668–669 - PubMed

[9] Singh SP, et al. 2011. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS 5:e960 - PMC - PubMed

[10] Singh SP, et al. 2011. Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS 5:e960 - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India

Affiliation

Post-kala-azar dermal leishmaniasis in a patient treated with injectable paromomycin for visceral leishmaniasis in India

Authors

Affiliation

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources